ClinicalTrials.Veeva

Menu

Involvement of Nervous System in Muscle Weakness in COPD Patients (DesCoM-1)

5

5 Santé

Status

Completed

Conditions

Chronic Obstructive Pulmonary Disease

Study type

Observational

Funder types

Other

Identifiers

NCT01679782
FVIE_FA1

Details and patient eligibility

About

The purpose of this study is to determine whether nervous system alterations and motor drive failure can contribute to muscle weakness in COPD during voluntary movement. If necessary, we will look after the role of nocturnal hypoxia in these alterations.

Full description

COPD is a common disease that induces many systemic repercussions. Among these, peripheral muscle dysfunction is particularly deleterious because it leads to the decreases of the level of activity and the quality of life for patients. Movement involves activation of many structures, from the instructor, i.e. the brain, to the effector, i.e. the muscle. Netherless, the studies which have described peripheral muscle dysfunction have been focused on the muscle, so they have proposed a reducing vision of the phenomenon. Other studies have reported cerebral alterations in COPD, like cognitive disturbance, increase of the neuronal conduction time, and decrease of the white matter density, and were associated with chronic hypoxemia. Such alterations are consistent with the existence of a decrease of the central motor drive during voluntary movement in COPD patients. Therefore the study will aim to determine precisely which mechanisms are involved in peripheral muscle dysfunction in copd.

Enrollment

137 patients

Sex

All

Ages

40 to 75 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • COPD Patients at stage 2 and 3
  • Healthy sedentary subjects

Exclusion criteria

  • Epilepsy, pace-maker, nervous disorders

Trial design

137 participants in 3 patient groups

COPD nocturnal desaturator
Description:
COPD patients who spend 30% of the nigth with a SaO2 \< 90%.
COPD no nocturnal desaturator
Description:
COPD patients who spend less than 30% of the night with a SaO2 \< 90%
control group
Description:
healthy sedentary subjects

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems